COVID-19 update - 27th of January 2023, CHMP meeting

Paxlovid (nirmatrelvir / ritonavir) - Pfizer Europe MA EEIG 

• Indication: a medicine used for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe 
• The committee recommended converting the conditional marketing authorisation to a standard marketing authorisation.